Silverback Therapeutics (NASDAQ:SBTX) Stock Price Down 6.9% - Here's Why

Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) was down 6.9% during mid-day trading on Monday . The company traded as low as $11.89 and last traded at $11.92. Approximately 1,370,275 shares traded hands during mid-day trading, an increase of 305% from the average daily volume of 337,931 shares. The stock had previously closed at $12.80.Silverback Therapeutics Stock Down 6.9 %The company has a market capitalization of $429.81 million, a price-to-earnings ratio of -4.93 and a beta of 0.60. The stock has a 50 day simple moving average of $12.32 and a 200 day simple moving average of $13.07. Silverback Therapeutics Company Profile (Get Free Report)Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.Featured StoriesFive stocks we like better than Silverback TherapeuticsTSX Venture Exchange (Formerly Canadian Venture Exchange)Merck: 4 No-Brainer Reasons to Buy This Dip Find and Profitably Trade Stocks at 52-Week LowsAckman Announces Major Stake in Uber: Should You Follow His Lead?What Are the FAANG Stocks and Are They Good Investments?Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand OutThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Where Should You Invest $1,000 Right Now?Before you make your next trade, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.They believe these five stocks are the five best companies for investors to buy now...See The Five Stocks Here Should You Invest $1,000 in Silverback Therapeutics Right Now?Before you consider Silverback Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.While Silverback Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here